***
FDA has granted Teva Phamaceuticals approval to produce a generic version of Truvada. It’s important to note that there are number of factors involved in commercialization that are not tied directly to FDA approval.
A generic version of Truvada will not be immediately available. The patent for tenofovir disoproxil fumarate (TDF), a component of Truvada, expires July 2017 and has pediatric exclusivity until January 2018. The patent for emtricitabine, a component of Truvada, expires in 2021.
Gilead believes Truvada for PrEP is an important HIV prevention tool and we remain committed to helping ensure access to our medications for people both at risk of or living with HIV.